00:29 , Mar 15, 2019 |  BC Week In Review  |  Clinical News

Syndax pauses entinostat-PD-1/PD-L1 combo program

Syndax said in its 4Q18 financial results that it will "defer advancement" of its program evaluating entinostat plus PD-1/PD-L1 inhibitors after the combinations missed the primary endpoints of improving progression-free survival (PFS) in a pair...
03:19 , Nov 2, 2018 |  BC Innovations  |  Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
00:29 , Oct 20, 2017 |  BC Week In Review  |  Company News

Syndax licenses menin-MLL inhibitors from Allergan

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) obtained an exclusive, worldwide license to inhibitors of the menin-MLL fusion oncogene from the Vitae Pharmaceuticals Inc. subsidiary of Allergan plc (NYSE:AGN). Syndax plans to begin clinical trials in 2019 of...
20:21 , Oct 17, 2017 |  BC Extra  |  Company News

Syndax in menin-MLL deal with Allergan

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) obtained an exclusive, worldwide license to inhibitors of the menin-MLL fusion oncogene from the Vitae Pharmaceuticals Inc. subsidiary of Allergan plc (NYSE:AGN). Syndax plans to begin clinical trials in 2019 of...
07:00 , May 4, 2015 |  BC Week In Review  |  Company News

University of Michigan, Kura Oncology deal

Last December, the university granted Kura exclusive, worldwide rights to a class of preclinical small molecule inhibitors targeting menin-MLL fusion oncogene , including MI-463 and MI-503 . Preclinical data published in Cancer Cell and Nature...
07:00 , Apr 23, 2015 |  BC Innovations  |  Product R&D

Tapping menin

In a sign of the growing role of venture philanthropy in bridging the gap from academia to industry, a project backed by the Leukemia & Lymphoma Society has been licensed to Kura Oncology Inc. from...
07:00 , Apr 23, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Multiple endocrine neoplasia I (menin; MEN1); myeloid-lymphoid or mixed-lineage leukemia (MLL; HRX)

Cancer INDICATION: Prostate cancer Cell and mouse studies suggest inhibitors of the menin-MLL interaction could help treat prostate cancer. In prostate cancer patients, tumor levels of menin correlated with poor outcomes. In human prostate cancer...
07:00 , Apr 9, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Multiple endocrine neoplasia I (MEN1; menin); myeloid-lymphoid or mixed-lineage leukemia (MLL; HRX)

Cancer INDICATION: Leukemia Studies in cells, mice and patient samples suggest inhibiting the menin-MLL interaction could help treat acute leukemias driven by MLL fusion oncogenes. Chemical synthesis and testing in cellular assays identified two lead...
07:00 , Mar 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myelogenous leukemia (AML); acute lymphoblastic leukemia (ALL) Myeloid-lymphoid or mixed-lineage leukemia (MLL; HRX); multiple endocrine neoplasia I (MEN1; menin) SAR studies suggest compounds that...
07:00 , Oct 11, 2012 |  BC Innovations  |  Strategy

Leukemia team building

The Leukemia & Lymphoma Society has announced its first research partnership with a large biopharma company-a four-year, multimillion-dollar deal with Celgene Corp. to solicit and fund proposals from academics and smaller biotechs. The not-for-profit organization...